Almirall Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting

Results from Phase III pivotal studies to be featured at Late-Breaking Research Program on March 2 nd , 2019 Almirall and Athenex entered into a strategic partnership in December 2017 to develop and commercialize KX2-391 for actinic keratosis in the United States and Europe

The release as fetched from its publisher. almirall.com ↗